Phase 1 Study of CVD 1208S-122 Shigella-ETEC Vaccine

Phase 1, randomised, double-blind trial of CVD 1208S-122 in Shigella infection and enterotoxigenic Escherichia coli infection (4 cohorts), sponsored by University of Maryland, Baltimore. Primary endpoints: Participants Experiencing Fever, Diarrhea, or Dysentery; Solicited Local Adverse Events; Solicited Systemic Adverse Events; and Clinical Safety Laboratory Adverse Events at 36 days, Vaccine Organisms Shed in Stools in Cohorts 1-3 at 7 days and 2 more. Started Sep 2022; status: completed.